Skip NavigationSkip to Content
Return Return to Search Results

ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION

  1. Author:
    Beigel, J. H.

  2. Author Address

    NCI, Immunoregulat Lab, Div Intramural Res, NIAID,SAIC Frederick Inc,NIH, Frederick, MD 21702 USA.;Beigel, JH, NCI, Immunoregulat Lab, Div Intramural Res, NIAID,SAIC Frederick Inc,NIH, Frederick, MD 21702 USA.;jbeigel@niaid.nih.gov
    1. Year: 2010
    2. Date: May
  2. Journal: Drugs of the Future
    1. 35
    2. 5
    3. Pages: 385-392
  4. Type of Article: Review
  5. ISSN: 0377-8282
  1. Abstract:

    The recent pandemic of H1N1 has demonstrated the potential vulnerability of the human population to novel influenza viruses. While there is recent increased interest and effort in developing effective anti-influenza agents, few new products have entered clinical studies. This review will highlight the limited armamentarium of licensed influenza agents, and discuss novel compounds and strategies that have entered clinical studies and may therefore be imminently available to the treating clinician.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1358/dof.2010.35.5.1487081
  3. View record in Web of Science®
  4. WOS: 000280018100004

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel